论文部分内容阅读
目的探讨痰热清在慢性阻塞性肺疾病(COPD)急性加重期患者肺炎支原体感染中的临床疗效,为临床用药提供依据。方法回顾性分析医院2012年2月-2013年2月收治的400例COPD急性加重期肺炎支原体感染患者的临床资料,随机分为治疗组和对照组各200例,对照组患者单用头孢曲松、头孢唑肟、头孢他啶等第三代头孢菌素类抗菌药物治疗,治疗组患者在以上抗菌药物治疗外加用痰热清治疗,比较两组患者的临床疗效和治疗前后临床症状改善;所有数据采用SPSS13.0软件进行统计分析。结果治疗30d后总有效率治疗组96.00%、对照组88.50%,两组比较差异有统计学意义(P<0.05);治疗前两组患者的临床症状例数均差异无统计学意义;治疗后临床症状与体征改善率对照组患者咳嗽、咳痰、发热、肺部痰鸣音、气喘及口唇紫绀分别为87.8%、87.5%、87.5%、96.1%、97.7%、100.0%,治疗组患者分别为96.6%、97.3%、98.5%、97.9%、100.0%、100.0%。结论痰热清在COPD急性加重期肺炎支原体感染中的临床疗效显著。
Objective To investigate the clinical efficacy of Tanreqing in patients with Mycoplasma pneumoniae infection in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD), and to provide evidence for clinical use. Methods The clinical data of 400 patients with mycoplasma pneumoniae infection in the hospital from February 2012 to February 2013 were retrospectively analyzed. They were randomly divided into treatment group (200 cases) and control group (200 cases). Patients in the control group were treated with ceftriaxone , Ceftizoxime, ceftazidime and other third-generation cephalosporins antibacterial drugs in the treatment group in addition to antibiotics plus Tanreqing treatment, the clinical efficacy of two groups were compared and before and after treatment to improve clinical symptoms; all data using SPSS13.0 software for statistical analysis. Results After treatment for 30 days, the total effective rate was 96.00% in the treatment group and 88.50% in the control group, with significant difference between the two groups (P <0.05). There was no significant difference in the number of clinical symptoms between the two groups before treatment Clinical symptoms and signs of improvement in the control group were 87.8%, 87.5%, 87.5%, 96.1%, 97.7%, 100.0% cough, sputum, fever, lung phlegm, asthma and lip cyanosis respectively 96.6%, 97.3%, 98.5%, 97.9%, 100.0%, 100.0%. Conclusion Tanreqing in the acute exacerbation of COPD Mycoplasma pneumoniae infection in the clinical efficacy of significant.